PI3K/Akt/mTOR Pathway

PI3K/AKT/mTOR pathway is an intracellular signaling pathway that plays a key role in the control of cell cycle. PI3K is a dimer composed of regulatory subunit p85 and catalytic subunit p110. When it binds to growth factor receptors, it can alter the protein structure of Akt and activate it, and activate or inhibit a series of downstream substrates such as mTOR activity by phosphorylation, thus regulating cell proliferation, differentiation, apoptosis, and migration phenotypes.

Cat. No.	Product name
BP22280	(Z)-GW 5074
(Z)-GW 5074 interacts with both mHTT (mutant huntingtin protein) and LC3.
BP22281	9,9'-Di-O-(E)-feruloylsecoisolariciresinol
1,4-O-Diferuloylsecoisolariciresinol(9,9'-Di-O-(E)-feruloylsecoisolariciresinol),and pierreione B, two novel inhibitors of mTOR signaling, have strong anticancer activity. (+)-9,9'-O-Diferuloylsecoisolariciresinol has significant cytotoxic activity against the DU145, LNCaP, and A549 cell lines.
BP22282	1-Azakenpaullone
1-Azakenpaullone is a potent and selective GSK-3β inhibitor with IC50 of 18 nM, >100-fold selectivity over CDK1/cyclin B and CDK5/p25.
BP22283	A 1070722
A 1070722 is a potent and selective GSK-3 inhibitor, shows high affinity GSK-3α(Ki = 0.6 nM) and GSK-3β(Ki = 0.6 nM). It can penetrate the blood-brain barrier (BBB) and accumulates in brain regions, thus potential for PET radiotracer for the quantification of GSK-3 in brain.
BP22284	AMG319
AMG319 is a potent and selective PI3Kδ inhibitor with IC50 of 18 nM, >47-fold selectivity over other PI3Ks. Phase 2.
BP22285	AS-604850
AS-604850 is a specific and ATP-competitive PI3Kγ inhibitor (IC50: 250 nM), 18-fold more selective for PI3Kγ than PI3Kα, and over 80-fold selectivity for PI3Kγ than PI3Kδ/β.
BP22286	AZD1080
AZD1080 is a selective, orally active, brain permeable GSK3 inhibitor.
BP22287	AZD8186
AZD8186 is an effective and specific PI3Kβ/δ inhibitor (IC50: 4/12 nM).
BP22288	AZD-8835
AZD8835 is a mixed inhibitor of PI3Kα/δ (IC50: 6.2/5.7 nM), also with selectivity against PI3Kβ/γ (IC50: 431/90 nM).
BP22289	TMBIM6 antagonist-1
BIA is a bax inhibitor
BP22290	BIP-135
BIP-135 is a potent and selective ATP-competitive GSK-3 inhibitor. With IC50s of 16 nM and 21 nM for GSK-3α and GSK-3β, respectively. BIP 135 exhibits neuroprotective effect.
BP22291	BRD0705
BRD0705 is a potent, paralog selective and orally active GSK3α inhibitor (IC50: 66 nM; Kd: 4.8 μM). BRD0705 displays increased selectivity for GSK3α (8-fold) versus GSK3β (IC50: 515 nM).
BP22292	Charantin
Charantin is a steroidal saponin isolated from Momordica charantia. It increases the release of insulin and slowing down gluconeogenesis. Charantin can inhibit GSK-3.
BP22293	CZ415
CZ415 is a potent and highly selective mTOR inhibitor.
BP22294	Desmethyl-VS-5584
Desmethyl-VS-5584 is a dimethyl analog of VS-5584, which is a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer.
BP22295	DMH-25
DMH25 is a novel covalent and potent inhibitor of mTOR and shows in vivo antitumor activity against triple-negative breast cancer cells.
BP22296	FT-1518
FT-1518,exhibits antitumor activity, is a new generation selective, potent and oral bioavailable mTORC1 and mTORC2 inhibitor.
BP22297	GDC-0326
GDC-0326 is a potent and selective inhibitor of α-Isoform of Phosphoinositide 3-Kinase (PI3Kalpha inhibitor).
BP22298	GNE-477
GNE-477 is a potent and efficacious dual PI3K/mTOR inhibitor.
BP22299	GNE-493
GNE-493 is potent, selective, and orally available PI3K and mTOR inhibitor with potential anticancer activity.IC50s of 3.4 nM, 12 nM, 16 nM, 16 nM and 32 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR,respectively.

Cat. No.

Product name

BP22280

(Z)-GW 5074

(Z)-GW 5074 interacts with both mHTT (mutant huntingtin protein) and LC3.

BP22281

9,9'-Di-O-(E)-feruloylsecoisolariciresinol

1,4-O-Diferuloylsecoisolariciresinol(9,9'-Di-O-(E)-feruloylsecoisolariciresinol),and pierreione B, two novel inhibitors of mTOR signaling, have strong anticancer activity. (+)-9,9'-O-Diferuloylsecoisolariciresinol has significant cytotoxic activity against the DU145, LNCaP, and A549 cell lines.

BP22282

1-Azakenpaullone

1-Azakenpaullone is a potent and selective GSK-3β inhibitor with IC50 of 18 nM, >100-fold selectivity over CDK1/cyclin B and CDK5/p25.

BP22283

A 1070722

A 1070722 is a potent and selective GSK-3 inhibitor, shows high affinity GSK-3α(Ki = 0.6 nM) and GSK-3β(Ki = 0.6 nM). It can penetrate the blood-brain barrier (BBB) and accumulates in brain regions, thus potential for PET radiotracer for the quantification of GSK-3 in brain.

BP22284

AMG319

AMG319 is a potent and selective PI3Kδ inhibitor with IC50 of 18 nM, >47-fold selectivity over other PI3Ks. Phase 2.

BP22285

AS-604850

AS-604850 is a specific and ATP-competitive PI3Kγ inhibitor (IC50: 250 nM), 18-fold more selective for PI3Kγ than PI3Kα, and over 80-fold selectivity for PI3Kγ than PI3Kδ/β.

BP22286

AZD1080

AZD1080 is a selective, orally active, brain permeable GSK3 inhibitor.

BP22287

AZD8186

AZD8186 is an effective and specific PI3Kβ/δ inhibitor (IC50: 4/12 nM).

BP22288

AZD-8835

AZD8835 is a mixed inhibitor of PI3Kα/δ (IC50: 6.2/5.7 nM), also with selectivity against PI3Kβ/γ (IC50: 431/90 nM).

BP22289

TMBIM6 antagonist-1

BIA is a bax inhibitor

BP22290

BIP-135

BIP-135 is a potent and selective ATP-competitive GSK-3 inhibitor. With IC50s of 16 nM and 21 nM for GSK-3α and GSK-3β, respectively. BIP 135 exhibits neuroprotective effect.

BP22291

BRD0705

BRD0705 is a potent, paralog selective and orally active GSK3α inhibitor (IC50: 66 nM; Kd: 4.8 μM). BRD0705 displays increased selectivity for GSK3α (8-fold) versus GSK3β (IC50: 515 nM).

BP22292

Charantin

Charantin is a steroidal saponin isolated from Momordica charantia. It increases the release of insulin and slowing down gluconeogenesis. Charantin can inhibit GSK-3.

BP22293

CZ415

CZ415 is a potent and highly selective mTOR inhibitor.

BP22294

Desmethyl-VS-5584

Desmethyl-VS-5584 is a dimethyl analog of VS-5584, which is a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer.

BP22295

DMH-25

DMH25 is a novel covalent and potent inhibitor of mTOR and shows in vivo antitumor activity against triple-negative breast cancer cells.

BP22296

FT-1518

FT-1518,exhibits antitumor activity, is a new generation selective, potent and oral bioavailable mTORC1 and mTORC2 inhibitor.

BP22297

GDC-0326

GDC-0326 is a potent and selective inhibitor of α-Isoform of Phosphoinositide 3-Kinase (PI3Kalpha inhibitor).

BP22298

GNE-477

GNE-477 is a potent and efficacious dual PI3K/mTOR inhibitor.

BP22299

GNE-493

GNE-493 is potent, selective, and orally available PI3K and mTOR inhibitor with potential anticancer activity.IC50s of 3.4 nM, 12 nM, 16 nM, 16 nM and 32 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR,respectively.